UPC

+ Watchlist + Portfolio

Universe Pharmaceuticals Inc

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.31
52-Week Range: $2.00 – $17.96
Market Cap: $22.61M
P/E (TTM): —
EPS (TTM): -1.38
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.05
PEG Ratio: —
Return on Equity: -3.50%
Return on Assets: -1.72%
Gross Margin: 36.52%
Operating Margin: -16.60%
Profit Margin: -10.95%
Current Ratio: 4.05
Debt/Equity: 0.17
Total Debt: $9.55M
Free Cash Flow: $-21.43M
Revenue Growth: -1.30%
Earnings Growth: —
Enterprise Value: $-16.96M

UPC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$40.14M	$32.31M	$23.02M	$17.86M
Cost of Revenue	$18.25M	$21.99M	$16.95M	$11.56M
Gross Profit	$21.89M	$10.32M	$6.07M	$6.30M
Research & Development	$7.64M	$4.86M	$3.60M	$671.76K
Selling, General & Admin	$20.84M	$9.00M	$9.88M	$8.00M
Operating Expenses	$28.91M	$14.28M	$14.09M	$9.22M
Operating Income	-$7.02M	-$3.97M	-$8.02M	-$2.92M
EBITDA	-$6.40M	-$3.66M	-$7.36M	-$2.92M
Pretax Income	-$7.09M	-$4.33M	-$8.12M	-$3.67M
Income Tax	$815.32K	$2.25M	$606.70K	$0.00
Net Income	-$7.91M	-$6.58M	-$8.73M	-$3.67M
Diluted EPS	-1335.29	-1089.21	-626.96	-8.06
Diluted Shares	5923	6042	13920	455871

UPC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.71M	$5.29M	$29.50M	$33.59M
Receivables	$15.18M	$12.52M	$17.88M	$13.19M
Inventory	$2.21M	$3.34M	$1.74M	$2.19M
Current Assets	$41.51M	$25.27M	$51.64M	$53.60M
Total Assets	$59.54M	$41.72M	$67.95M	$69.30M
Current Liabilities	$13.10M	$13.75M	$20.31M	$13.17M
Long-Term Debt	—	—	$2.14M	—
Total Debt	$3.94M	$5.48M	$7.99M	$9.26M
Total Liabilities	$13.10M	$13.75M	$22.45M	$13.17M
Retained Earnings	$16.32M	-$1.44M	-$10.17M	-$13.84M
Shareholders' Equity	$46.44M	$27.97M	$45.50M	$56.13M
Working Capital	$28.41M	$11.52M	$31.32M	$40.43M
Net Debt	—	$197.21K	—	—

UPC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$1.30M	$1.12M	-$9.51M	-$5.05M
Capital Expenditure	-$93.70K	-$44.17K	-$363.09K	-$347.19K
Free Cash Flow	-$1.40M	$1.07M	-$9.87M	-$5.40M
Depreciation & Amortisation	$533.95K	$508.79K	$485.73K	$517.43K
Investing Cash Flow	-$3.91M	-$44.17K	-$361.29K	-$341.81K
Financing Cash Flow	$3.32M	-$1.39M	$33.95M	$9.73M
Dividends Paid	$0.00	—	—	—
Net Change in Cash	-$1.89M	-$318.04K	$24.09M	$4.33M

UPC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q3 2025	Q1 2026
Cash & Equivalents	$47.27M	$33.59M	$27.56M
Receivables	$13.53M	$13.19M	$15.24M
Inventory	$3.57M	$2.19M	$1.98M
Current Assets	$65.03M	$53.60M	$55.21M
Total Assets	$80.67M	$69.30M	$71.47M
Current Liabilities	$23.42M	$13.17M	$13.65M
Long-Term Debt	$2.07M	—	$2.17M
Total Debt	$7.73M	$9.26M	$9.55M
Total Liabilities	$25.48M	$13.17M	$15.82M
Retained Earnings	-$13.46M	-$13.84M	-$15.40M
Shareholders' Equity	$55.18M	$56.13M	$55.65M
Working Capital	$41.61M	$40.43M	$41.56M

Market Snapshot

About

Universe Pharmaceuticals is a pharmaceutical company focusing on the manufacturing and sale of traditional Chinese medicine and dietary supplements. The company produces a range of healthcare products including antibiotic and anti-inflammatory medications. Universe Pharmaceuticals operates primarily in the Chinese market.